FDA DIRECT-TO-CONSUMER BROADCAST GUIDANCE TO BE EVALUATED AFTER TWO YEARS; "ADEQUATE PROVISION" OF LABELING POSSIBLE THROUGH FOUR-PART APPROACH
Executive Summary
FDA will re-examine its direct-to-consumer broadcast policy in two years to assess the effect of its proposal to relax the brief summary requirement in TV and radio ads, the agency said in an Aug. 8 Federal Register notice.
You may also be interested in...
DTC Decennial Survey: FDA Adds Nurses, Physician Assistants To Queries On Ads
The survey will update findings from a 2002 assessment by physicians on the impact of DTC marketing on their interactions with patients.
Risk Disclosure In Drug Ads Will Be FDA’s Focus After House Defeats DTC Ban
The revised language on direct-to-consumer advertising in the FDA safety bills pending in Congress no longer allows the agency to ban ads, but creates a number of new disclosure requirements for the spots
Risk Disclosure In Drug Ads Will Be FDA’s Focus After House Defeats DTC Ban
The revised language on direct-to-consumer advertising in the FDA safety bills pending in Congress no longer allows the agency to ban ads, but creates a number of new disclosure requirements for the spots